Holen Sie sich die Stockscreener-App
12.00
2.30%
0.27
Handel nachbörslich:
12.00
Schlusskurs vom Vortag:
$11.73
Offen:
$11.7
24-Stunden-Volumen:
818.44K
Relative Volume:
0.97
Marktkapitalisierung:
$4.45B
Einnahmen:
$4.79B
Nettoeinkommen (Verlust:
$-317.00M
KGV:
-13.19
EPS:
-0.91
Netto-Cashflow:
$-59.00M
1W Leistung:
-1.64%
1M Leistung:
+6.29%
6M Leistung:
-32.70%
1J Leistung:
-19.62%
1-Tages-Spanne:
$11.63
$12.05
1-Wochen-Bereich:
$11.44
$12.14
52-Wochen-Spanne:
$10.45
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
12.00 | 4.45B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
515.09 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.72 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.35 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
254.52 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
216.70 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Bausch + Lomb prices €675 million in senior secured notes - Investing.com
Bausch + Lomb Upsizes Note Offering And Secures New Loans - Finimize
Bausch + Lomb Strengthens Financial Position with €675M Notes and $3.1B Credit Package - Stock Titan
Bausch + Lomb announces €600m senior secured notes offering - Investing.com
Bausch + Lomb Has Promising Growth, But Lower Entry Points Likely Soon - Seeking Alpha
Bausch + Lomb’s SWOT analysis: ophthalmology leader faces headwinds in stock outlook - Investing.com
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement - BioSpace
Bausch + Lomb (NYSE:BLCO) Price Target Cut to $16.00 by Analysts at Barclays - Defense World
Kalkine: Examines Bausch + Lomb (NYSE:BLCO) and Its Dividend Yield Signals - Kalkine Media
Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | - GuruFocus
Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Barclays Analyst | - GuruFocus
Barclays reduces Bausch & Lomb stock price target to $16 - Investing.com Australia
Barclays reduces Bausch & Lomb stock price target to $16 By Investing.com - Investing.com Nigeria
BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm - Business Wire
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.
Bausch + Lomb (BLCO) Introduces New Lubricating Eye Drops in U.S - GuruFocus
Breakthrough Eye Drops: Bausch + Lomb Launches First-Ever Vitamin-Enriched Formula for Dry Eye Relief - Stock Titan
Bausch + Lomb Co. (NYSE:BLCO) Short Interest Update - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Bausch & Lomb Corp (BLCO) Trading Down 3.41% on May 30 - GuruFocus
Cetera Investment Advisers Decreases Stock Holdings in Bausch + Lomb Co. (NYSE:BLCO) - Defense World
Public market insider buying at Bausch + Lomb (BLCO) - The Globe and Mail
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo Finance
Bausch + Lomb’s SWOT analysis: stock outlook amid market challenges - Investing.com
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference - BioSpace
Bausch & Lomb shareholders approve board nominees and compensation - Investing.com
Bausch + Lomb shareholders elect 10 directors at annual meeting By Investing.com - Investing.com India
Bausch + Lomb shareholders elect 10 directors at annual meeting - Investing.com
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results - Yahoo Finance
Bausch + Lomb (BLCO) Launches LUMIFY Preservative Free Eye Drops in the U.S. | BLCO Stock News - GuruFocus
Bausch + Lomb introduces Zenlens CHROMA HOA lenses By Investing.com - Investing.com Canada
Bausch + Lomb introduces Zenlens CHROMA HOA lenses - Investing.com
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States - The Joplin Globe
Bausch + Lomb Co. (NYSE:BLCO) Given Average Recommendation of “Hold” by Analysts - Defense World
Morgan Stanley Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $12.00 - Defense World
Bausch + Lomb’s LuxLife Intraocular Lens Gains European CE Mark Approval - TipRanks
Bausch + Lomb (BLCO) Receives CE Mark for LuxLife Intraocular Lens | BLCO Stock News - GuruFocus
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens - Stock Titan
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BLCO Stock News - GuruFocus
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BL - GuruFocus
20,600 Shares in Bausch + Lomb Co. (NYSE:BLCO) Bought by Renaissance Technologies LLC - Defense World
Citigroup Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch & Lomb stock target cut to $15 at H.C. Wainwright By Investing.com - Investing.com South Africa
Bausch & Lomb stock target cut to $15 at H.C. Wainwright - Investing.com Nigeria
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwr - GuruFocus
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwright & Co. | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Cut by Analyst Amid Tariff Concerns | BLCO Stock News - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Pr - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Price Target | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Shares Plunge After Weak Q1 2025 Results - GuruFocus
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bausch Lomb Corp-Aktie (BLCO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VON ESCHENBACH ANDREW C. | Director |
May 02 '25 |
Buy |
11.76 |
1,695 |
19,925 |
41,748 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Aug 05 '24 |
Buy |
15.66 |
32,250 |
505,067 |
595,169 |
0.43%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):